A dramatic incident unfolded at the Oval Office today during a press briefing when a pharmaceutical executive suddenly collapsed. The individual, who was positioned behind the US President, was participating in an event where the Trump administration was introducing a new agreement related to weight-loss medications, when he unexpectedly lost his balance and fell.
Upon witnessing the collapse, administration officials and representatives from the pharmaceutical industry swiftly rushed to assist the affected individual, preventing him from hitting the ground. White House Press Secretary Karoline Leavitt clarified that during the ‘Most Favored Nations Oval Office Announcement’, a representative from one of the companies experienced a fainting spell.
Medical staff on-site promptly attended to the individual, ensuring his well-being. Leavitt assured the gathered audience that the person involved was ultimately fine and that the press conference would resume shortly. The official statement released stated, “During the Most Favored Nations Oval Office Announcement, a representative with one of the companies fainted. The White House Medical Unit quickly jumped into action, and the gentleman is okay. The Press Conference will resume shortly.”
Following the incident, reporters were escorted out of the Oval Office to allow cabinet members to provide assistance to the collapsed individual and elevate his legs. The cause of the collapse remains unknown at this time.
The press conference showcased executives from pharmaceutical giants Novo Nordisk and Eli Lilly standing alongside the Trump administration to unveil a groundbreaking deal that could significantly impact the healthcare sector. Under the agreement, the manufacturers of Ozempic, Wegovy, and Zepbound will offer their in-demand treatments directly to the public through TrumpRx, a forthcoming government website.
In a significant development for patients, the companies announced that an oral version of the medications could potentially be priced at $149 (£113) per month pending FDA approval. Additionally, individuals covered by Medicare or Medicaid facing conditions like diabetes will witness a reduction in the cost of injectable versions to $245 (£186) per month.
For quick access to valuable news, consider designating Daily Mirror as a ‘Preferred Source’ on Google News.